by Wim Mees | Sep 21, 2023 | Team events
Congrats Lore Van Oudenhove, the winner of the first myNEO soccer cup! This summer we organised a table football cup where everyone of the team competed against each other. The third place playoff was won by Bruno Fant against Manon Montyne. Lore won the final after a...by Wim Mees | Jun 11, 2023 | Team events
Coming together is a beginning, staying together is progress, and working together is success! Just before summer we had a blast during the myNEO teambuilding where we had so much fun with different collaboration and competition games. While our team continues to...by Wim Mees | May 10, 2023 | Team events
Recently we enjoyed some delicious and freshly shaken, but not stirred, (m)(c)ocktails with the myNEO team. It was great catching up with everyone. #workhardplayhardThanks Deloitte for this great reward! #fast50 Enjoy the pictures !by Wim Mees | Oct 13, 2022 | Team events
At myNEO we know a company is only as strong as its team! Therefore, we recently built on that team relationship. In August we both had a team-BBQ together with our families and breakfast in the office with the board members.by Wim Mees | Aug 17, 2022 | Team events
Work hard, play hard!At myNEO we have afterwork drinks every month, this time we decided to enjoy the nice weather and have our well-deserved drinks at summer bar, Gazon. Some sun, refreshing drinks, and great colleagues made sure this was a fun and...by Wim Mees | Mar 1, 2022 | Team events
myNEO fully endorses a work hard/play hard balance and so we have at least once a month an afterwork drink or dinner. We think it is important to keep the team spirit alive to enable better interpersonal communication leading to more efficient team working...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).